Time to Load up on Atossa Shares? This Analyst Thinks So

TipRanks2021-06-15

The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

yuxii
2021-06-16
yuxii
yes
- BotakGuy:
  Ok
lynjo
2021-06-16
lynjo
Hmm.
woanderful
2021-06-15
woanderful
The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(
J90
2021-06-15
J90
Cool
ELee2723
2021-06-15
ELee2723
Hmm?
54ae95d
2021-06-15
54ae95d
[Smile] [Smile] [Smile] [Smile] [Smile] [Smile]

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2143973689?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-15 14:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2143973689","market":"us","top_or_hot":-1,"title":"Time to Load up on Atossa Shares? This Analyst Thinks So","media":"TipRanks","content":"<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">网页链接</a>\n\n</div>\n","source":"lsy1606183248679","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Time to Load up on Atossa Shares? This Analyst Thinks So</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTime to Load up on Atossa Shares? This Analyst Thinks So\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 14:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (...</p>\n\n<a href=\"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIME","symbol_name":"Clockwise Core Equity & Innovation ETF","start_time":0,"source_url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","article_id":"2143973689","we_media_id":null,"thumbnails":[],"rights":{"source":"lsy1606183248679","url":"https://www.tipranks.com/news/article/time-to-load-up-on-atossa-shares-this-analyst-thinks-so/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2143973689","pubTimestamp":1623739755,"sourceInfo":{"source_id":"lsy1606183248679","name":"TipRanks"},"weMediaInfo":null,"summary":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIME":"Clockwise Core Equity & Innovation ETF","ATOS":"Atossa Genetics Inc"},"translate_title":"是时候买Atossa的股票了？这位分析师是这么认为的","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9,"TIME":0.9,"TWX":0.9},"content_text":"The stock market, like any other industry, is riddled with clichés. One of the most commonly used is the ubiquitous “buy the rumor, sell the news.” However, clichés are not clichés without reason (another cliché...) and the old maxim could perfectly describe last week’s performance of Atossa Therapeutics (ATOS) stock.\nSince the end of April, shares had more than tripled in anticipation of the final results from the phase 2 clinical trial evaluating oral endoxifen, the biotech’s breast cancer treatment to be administered between diagnosis and surgery.\nThe company disclosed the results last week. With a 65.1% reduction in Ki-67 levels - a measure of tumor cell activity - the study met its primary endpoint. What’s more, all evaluated patients displayed a reduction of Ki-67 to levels below 25%, which shows the drug’s potential to improve long-term survival. The drug was also shown to be overall safe and well tolerated.\nNext up, the company said it has initiated a formal non-clinical toxicology program, a prerequisite for the New Drug Application to gain endoxifen’s entry to market. The company will also seek the FDA’s approval to move to the next stage of the clinical testing in the U.S.\nHowever, the shares dropped by 27% in the subsequent session, a clear case of the aforementioned \"buy the rumor, sell the news,” says Maxim’s Jason McCarthy.\n“Bottom line, is the data are positive and that there are no options for women during this period before surgery, a time in which the tumor can/will continue to grow,” the 5-star analyst said. “Additionally, with $138M in cash on the balance sheet as of 1Q21, the company has several years of runway and as such, we are lowering our discount rate to 25%, from 30%. With this much capital, Atossa should be able to continue to develop endoxifen in later stages.”\nAs a result, McCarthy also reduced the risk adjustment for endoxifen in the neoadjuvant breast cancer setting from 75% to 50%.\nThe implication for investors? McCarthy rates ATOS shares a Buy alongside a $7 price target. Shares could appreciate ~51%, should the analyst’s thesis play out in the coming months. \nOnly one other analyst is currently tracking Atossa’s progress, also believing the stock is a Buy, both coalescing a Moderate Buy consensus rating. The Moderate Buy consensus rating is backed by a $7.5 average price target, suggesting one-year upside of 62%. (See ATOS stock analysis on TipRanks)\n\nTo find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":160116270,"gmtCreate":1623774622190,"gmtModify":1634028406902,"author":{"id":"3570443255970408","authorId":"3570443255970408","name":"yuxii","avatar":"https://static.tigerbbs.com/72a96d0d673ad58e556302185ab1d594","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/160116270","repostId":2143973689,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4997186,"gmtCreate":1624543433893,"gmtModify":1635248236260,"authorId":3557831813182222,"author":{"id":3557831813182222,"authorId":3557831813182222,"name":"BotakGuy","avatar":"https://static.tigerbbs.com/f7a8a7afc7644e0f8f2635094f19c39d","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":160116270,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":160329233,"gmtCreate":1623773068822,"gmtModify":1634028468203,"author":{"id":"3582677476432732","authorId":"3582677476432732","name":"lynjo","avatar":"https://static.tigerbbs.com/2e27a74592895978b4a49574062e39e5","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Hmm.&nbsp;","listText":"Hmm.&nbsp;","text":"Hmm.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/160329233","repostId":2143973689,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187530288,"gmtCreate":1623758061844,"gmtModify":1634028897239,"author":{"id":"3583022959242714","authorId":"3583022959242714","name":"woanderful","avatar":"https://static.tigerbbs.com/4e5b04b7e9dab6f7f58cb053028db83d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(","listText":"The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(","text":"The growth of the stocks aside, it is good news that there are developmemts in this area as breast cancer is more prevelant :(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187530288","repostId":2143973689,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187614834,"gmtCreate":1623751985128,"gmtModify":1634029053043,"author":{"id":"3581487017513023","authorId":"3581487017513023","name":"J90","avatar":"https://static.tigerbbs.com/59b9bd5153d367d5ee88324bdf6c6003","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187614834","repostId":2143973689,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187881532,"gmtCreate":1623749262426,"gmtModify":1634029131252,"author":{"id":"3576576038240682","authorId":"3576576038240682","name":"ELee2723","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Hmm?","listText":"Hmm?","text":"Hmm?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187881532","repostId":2143973689,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":187893778,"gmtCreate":1623748469794,"gmtModify":1634029156357,"author":{"id":"3581547759733110","authorId":"3581547759733110","name":"54ae95d","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;","listText":"[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;","text":"[Smile] [Smile] [Smile] [Smile] [Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187893778","repostId":2143973689,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":24,"commentSize":13,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2143973689"}